New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex ...

Group 1: Ark Invest Portfolio Strategy - Ark Invest, led by Cathie Wood, focuses on aggressive investments in growth businesses pursuing disruptive innovation [1][2] - The portfolio recently increased its holdings in two biotech stocks, indicating a belief in their potential for success despite inherent risks [1][2] Group 2: Intellia Therapeutics - Intellia Therapeutics is a gene-editing biotech aiming to treat inherited rare diseases by editing dysfunctional genes [3][4] - The company has a late-stage program for transthyretin (ATTR) amyloidosis entering phase 3 trials and a mid-stage program for hereditary angioedema (HAE) with upcoming data [4][5] - Financially, Intellia reported approximately $940 million in cash and equivalents, with R&D expenses of about $449 million, providing a runway until late 2026 [5] - Risks include potential scientific or regulatory hurdles that could significantly impact the company's value [6][7] Group 3: Recursion Pharmaceuticals - Recursion Pharmaceuticals holds a focus on using artificial intelligence (AI) in drug development, with a pipeline of therapies for rare diseases [8][9] - The company is merging with Exscientia, expected to close in early 2025, which will enhance its cash position and oncology pipeline [9][10] - The merged entity will have around $850 million in cash and is projected to achieve $100 million in efficiencies post-transaction [10] - The new company anticipates up to 10 clinical data readouts in the next 18 months, presenting potential catalysts for stock movement [10][11] - Collaborations with major biopharma companies like Merck, Roche, and Nvidia suggest confidence in Recursion's future prospects [12][13]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. Intellia Therapeutics (NASDAQ: NTLA ) is one of the vanguard of companies that is attempting to convert the amazing and Nobel Prize winning technology of CRISPR/Cas9 into ...

Intellia Therapeutics, Inc. (NTLA) incurred second-quarter 2024 loss of $1.31 per share (excluding a one-time expense of change in fair value of investments), which was wider than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago quarter, Intellia had incurred a loss of $1.40 per share. Including the above one-time expense, the company reported a loss of $1.52 per share in the second quarter of 2024. The company's total revenues currently comprise only collaboration revenues. NTLA reported re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |---------------------------------------------------------------------------------|-----------------------| | | | | Commission File Number: 001-37766 | | ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations & Corporate Communications John Leonard - President & Chief Executive Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Mary Kate Davis - Bank of America Dae Gon Ha - Stifel Joseph Thome - TD Cowen Luca Issi - RBC ...

| --- | --- | --- | --- | --- | --- | |--------------------|-------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Intellia | is Leading the | | | | | | | Gene Editing Revolution | | | | | | | | | | | | | Corporate Overview | | | | | | | August 2024 | | | | | | | | | | | | | Intellia Therapeutics' Legal Disclaimer 2 This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.06, delivering a surprise of 21.48%. Over the last four quarters, the compan ...

Exhibit 99.1 E, LELEBELLI III PRESS RELEASE #11010101011111111 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter - Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 - Rapid enrollment continues in the Phase 3 MAGNIT ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...